Deprotected cyclic RGDyK CAS NO.250612-42-1

1. Min Hee Lee et al. Direct Fluorescence Monitoring of the Delivery and Celluar Uptake of a Cancer-Targeted RGD Peptides-Appended Naphthalimide Theragnostic Produrg. J. Am. Chem. Soc., 2012, 134, 12668-12674. 2. Won Jun Kang et al. Bioimaging of geographically adjacent proteins in a single cell by quantum dot-based fluorescent resonance energy transfer. Proteomics Clin. Appl. 2009, 3, 1383-1388. 3. Kyeongsoon Park et al. Tumor Endothelial Cell Targeted Cyclic RGD-modified Heparin Derivatives: Inhibition of Angiogenesis and Tumor Growth. Pharmaceutical Reserch, 2008, 25, 2786- 2798. 4. Yun-Sang Lee, Dae Yoon Chi et al. An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK). Nucl. Med. Biol., 2006, 33, 677-683. 5. Roland Haubner et al. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers Tumor Targeting. J. Nucl. Med., 1999, 40, 1061